Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Narrative (Details)

v3.8.0.1
Acquisitions, Investments, and Licenses - Narrative (Details) - USD ($)
1 Months Ended 12 Months Ended
Jul. 09, 2015
Nov. 30, 2017
Apr. 30, 2017
Aug. 31, 2016
Jun. 30, 2016
Jun. 30, 2012
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Jun. 30, 2015
Business Acquisition [Line Items]                    
Ownership percentage             4.00%      
Total assets of equity method investees             $ 396,300,000      
Total liabilities of equity method investees             201,800,000      
Net losses of equity method investees             130,900,000      
Market value of equity method investees             54,800,000      
Business combination, separately recognized transactions, net gains and losses               $ 2,500,000    
Gain (loss) on sale of investments             8,663,000 (2,321,000) $ (7,091,000)  
Gain on deconsolidation of SciVac             0 0 15,940,000  
Write down to other assets             8,800,000      
Common Stock                    
Business Acquisition [Line Items]                    
Stock price (in dollars per share)       $ 9.10            
Transition Therapeutics, Inc.                    
Business Acquisition [Line Items]                    
Total purchase price       $ 58,500,000            
Transition Therapeutics, Inc. | Common Stock                    
Business Acquisition [Line Items]                    
Common stock received, in shares (in shares)       6,431,899            
Eloxx Pharmaceuticals                    
Business Acquisition [Line Items]                    
Business combination, separately recognized transactions, net gains and losses             2,500,000      
Levon Resources Ltd                    
Business Acquisition [Line Items]                    
Stock ownership percentage 24.50%                  
Cash contribution             $ 21,200,000      
Cocrystal Pharma                    
Business Acquisition [Line Items]                    
Ownership percentage             9.00%      
Xenetic Biosciences, Inc.                    
Business Acquisition [Line Items]                    
Other-than-temporary impairment charge             $ 600,000      
Warrants to purchase common shares (in shares)             500,000      
RXi                    
Business Acquisition [Line Items]                    
Warrants to purchase common shares (in shares)             200,000      
Xenetic, RXi And ARNO                    
Business Acquisition [Line Items]                    
Other-than-temporary impairment charge               4,800,000    
NIMS                    
Business Acquisition [Line Items]                    
Ownership percentage             1.00%      
Neovasc                    
Business Acquisition [Line Items]                    
Ownership percentage             5.00%      
Warrants to purchase common shares (in shares)             4,900,000      
Payments to acquire equity method investments   $ 3,000,000                
BioCardia, Inc.                    
Business Acquisition [Line Items]                    
Ownership percentage             5.00%      
Warrants to purchase common shares (in shares)             400,000      
Vested warrants (in shares)             100,000      
Cocrystal                    
Business Acquisition [Line Items]                    
Warrants to purchase common shares (in shares)             1,000,000      
Payments to acquire equity method investments     $ 1,000,000 $ 2,000,000            
Chromadex Corporation                    
Business Acquisition [Line Items]                    
Available-for-sale investments, ownership percentage             1.00%      
MabVax                    
Business Acquisition [Line Items]                    
Available-for-sale investments, ownership percentage             2.00%      
MabVax | Common Stock                    
Business Acquisition [Line Items]                    
Warrants to purchase common shares (in shares)       415,800            
InCellDx Inc.                    
Business Acquisition [Line Items]                    
Warrants to purchase common shares (in shares)             700,000      
Eloxx Pharmaceuticals                    
Business Acquisition [Line Items]                    
Available-for-sale investments, ownership percentage             5.00%      
Zebra                    
Business Acquisition [Line Items]                    
Ownership percentage             29.00%      
Zebra | Series A Preferred Stock                    
Business Acquisition [Line Items]                    
Investment owned, shares (in shares)             1,260,000      
Zebra | Restricted Stock                    
Business Acquisition [Line Items]                    
Investment owned, shares (in shares)             900,000      
VBI Vaccines Inc                    
Business Acquisition [Line Items]                    
Payments to acquire equity method investments         $ 5,700,000          
Equity method investment, number of shares purchased in period         1,362,370          
Pharmsynthez                    
Business Acquisition [Line Items]                    
Ownership percentage             9.00%      
Levon Resources Ltd                    
Business Acquisition [Line Items]                    
Ownership percentage             10.00%      
InCellDx, Inc                    
Business Acquisition [Line Items]                    
Ownership percentage             29.00%      
RXi                    
Business Acquisition [Line Items]                    
Available-for-sale investments, ownership percentage             2.00%      
Other Income (Expense), Net                    
Business Acquisition [Line Items]                    
Gain (loss) on sale of investments             $ 1,500,000 $ 0 $ 0  
Other Operating Income (Expense) | SciVac                    
Business Acquisition [Line Items]                    
Gain on deconsolidation of SciVac             $ 15,900,000      
Variable Interest Entity, Not Primary Beneficiary | Zebra                    
Business Acquisition [Line Items]                    
Ownership percentage             29.00%      
Variable Interest Entity, Primary Beneficiary | SciVac                    
Business Acquisition [Line Items]                    
Stock ownership percentage           50.00%        
Additional working capital                   $ 7,900,000